Loading...
Loading...
LIAN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 28.4M |
| Operating I/L | -28.4M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.3M |
| Pretax | -27.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -27.7M |
LianBio is a biopharmaceutical company focused on developing and commercializing innovative medicines for a range of diseases including cardiovascular, oncology, respiratory, ophthalmology, and inflammatory conditions in China and other Asian countries. The company's product pipeline includes mavacamten for hypertrophic cardiomyopathy and heart failure, TP-03 for Demodex blepharitis, NBTXR3 for head and neck squamous cell carcinoma, Infigratinib for cholangiocarcinoma and gastric cancers, and other potential treatments for solid tumors, ulcerative colitis, Crohn's disease, chronic rhinosinusitis, and respiratory syncytial virus.
